In the BioHarmony Drug Report Database

"Preview" Icon

Vandetanib

Caprelsa (vandetanib) is a small molecule pharmaceutical. Vandetanib was first approved as Caprelsa on 2011-04-06. It is used to treat thyroid neoplasms in the USA. It has been approved in Europe to treat thyroid neoplasms. The pharmaceutical is active against proto-oncogene tyrosine-protein kinase receptor Ret and vascular endothelial growth factor receptor 2. In addition, it is known to target epidermal growth factor receptor. Caprelsa’s patents are valid until 2028-08-08 (FDA).

 

Trade Name

 

Caprelsa
 

Common Name

 

vandetanib
 

ChEMBL ID

 

CHEMBL24828
 

Indication

 

thyroid neoplasms
 

Drug Class

 

Angiogenesis inhibitors

Image (chem structure or protein)

Vandetanib structure rendering